Inventiva (NASDAQ:IVA) Given New $20.00 Price Target at Stifel Nicolaus

Inventiva (NASDAQ:IVA) had its target price lowered by Stifel Nicolaus from $25.00 to $20.00 in a report issued on Thursday morning, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Inventiva Trading Up 2.8 %

NASDAQ:IVA opened at $1.84 on Thursday. Inventiva has a 1-year low of $1.53 and a 1-year high of $4.75. The company’s 50-day moving average is $2.25 and its two-hundred day moving average is $2.96.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC purchased a new position in shares of Inventiva S.A. (NASDAQ:IVA) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,490 shares of the company’s stock, valued at approximately $38,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.